{"disease":{"id":"crizotinib","name":"crizotinib"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01945021","title":"Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03718117","title":"Descriptive Observational Study ALK-2016-CPHG","phase":"","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Pfizer","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}